Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORAb-202 in Selected Tumor Types
NCT04300556Phase 2Recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2020
- Primary completion
- Aug 2030
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 5
01
Overview
Phase 2, open-label trial of farletuzumab ecteribulin in ovarian cancer, endometrial cancer (EC), non-small cell lung carcinoma (NSCLC) and 1 more (6 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Recommended Phase 2 Dose, Recommended Dose up to 5 years and 3 more. Started Aug 2020; status: recruiting.
02
Drugs
farletuzumab ecteribulin
03
Conditions
ovarian cancerendometrial cancer (EC)non-small cell lung carcinoma (NSCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04300556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04300556.